MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ARDX stock logo

ARDX

Ardelyx, Inc.

$5.94
-0.17
 (-2.78%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  1.457B
Shares Outstanding:  13.345M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Michael G. Raab
Full Time Employees:  395
Address: 
400 Fifth Avenue
Waltham
MA
2451
US
Website:  https://www.ardelyx.com
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/01 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue124,456333,615407,320
Gross Profit106,661283,059367,783
EBITDA-55,354-16,713-29,173
Operating Income-63,276-27,950-40,977
Net Income-66,067-39,136-61,599

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets297,579435,754501,604
Total Liabilities130,763262,465334,655
Total Stockholders Equity166,816173,289166,949
Total Debt55,982153,438207,954
Cash and Cash Equivalents21,47064,93267,999

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-89,717-44,809-42,483
Capital Expenditure-344-1,011-1,492
Free Cash Flow-90,061-45,820-43,975
Net Income-66,067-39,136-61,599
Net Change in Cash-74,67043,4623,067

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,337,266.108Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,452,793.675Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,394,998.460Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-745,714.959Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-686,414.980Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-716,048.836Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)520,939.015Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)580,211.624Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)550,559.652Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,025,616.765Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,287,002.394Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)3,156,238.465Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)2.280Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)2.410Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)2.160Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
333.615M  ?P/S
 (TTM)
: 
3.88
?Net Income
 (TTM)
: 
-39136000  ?P/E
 (TTM)
: 
-25.51
?Enterprise Value
 (TTM)
: 
1.725B  ?EV/FCF
 (TTM)
: 
-39.24
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.41  ?ROIC
 (TTM)
: 
-0.1
?Net Debt
 (TTM)
: 
-96662000  ?Debt/Equity
 (TTM)
: 
1.27
?P/B
 (TTM)
: 
9.41  ?Current Ratio
 (TTM)
: 
4.31

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
37.13Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ARDX Intrinsic Value

Common questions about ARDX valuation

Is Ardelyx, Inc. (ARDX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Ardelyx, Inc. (ARDX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ARDX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ARDX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ARDX’s P/E ratio?

You can see ARDX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ARDX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ARDX a good long-term investment?

Whether ARDX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ARDX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

-2.78
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Ardelyx President and CEO Sells 41,000 Shares for $243,000
03-04-2026 11:11
Ardelyx President and CEO Sells 41,000 Shares for $243,000
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy
Ardelyx: Assessment Of Acquisition Rumors
Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read